Frazier Life Sciences Management, L.P. Rhythm Pharmaceuticals, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.59 Billion
- Q1 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 678,760 shares of RYTM stock, worth $44.6 Million. This represents 2.26% of its overall portfolio holdings.
Number of Shares
678,760
Previous 1,869,808
63.7%
Holding current value
$44.6 Million
Previous $105 Million
65.6%
% of portfolio
2.26%
Previous 6.27%
Shares
9 transactions
Others Institutions Holding RYTM
# of Institutions
245Shares Held
63.1MCall Options Held
403KPut Options Held
62.8K-
Black Rock Inc. New York, NY6.74MShares$443 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$400 Million6.69% of portfolio
-
Primecap Management CO Pasadena, CA5.79MShares$381 Million0.26% of portfolio
-
Baker Bros. Advisors LP New York, NY5.6MShares$369 Million3.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.44MShares$227 Million0.0% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.66B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...